Lui, Arthur <br/><br/>
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.  [electronic resource] 

 -  Investigational new drugs  08 2018 
 - 674-682 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-018-0599-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Capecitabine--administration & dosage<br/>Drug Administration Schedule<br/>Esophageal Neoplasms--drug therapy<br/>Esophagogastric Junction--drug effects<br/>Female<br/>Humans<br/>Irinotecan--administration & dosage<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Oxaliplatin--administration & dosage<br/>Stomach Neoplasms--drug therapy<br/>Young Adult